Plain-English translation of NCT04484012 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination treatment for mantle cell lymphoma—a rare blood cancer that has come back or stopped responding to previous treatments. The combination includes , a targeted medication, along with specially modified immune cells (called CAR T cells) that are designed to recognize and attack cancer cells. The goal is to see if this combination works better and is safe when used together.
Mantle cell lymphoma can be difficult to treat, especially when it returns or stops responding to standard therapies. Researchers want to find out whether combining this medication with engineered immune cells might help patients achieve better, longer-lasting responses to treatment.
You likely qualify if…
You likely don't qualify if…
You will continue taking by mouth twice daily throughout the study. On day 0, you will receive an infusion of the specially modified immune cells through an IV. You may receive a second infusion in cycle 2 if needed. Treatment continues for up to 6 cycles (each cycle is 28 days), with regular clinic visits for blood work, scans, and health monitoring. After treatment ends, you will have follow-up visits at 3, 6, and 12 months, then yearly for up to 15 years to track how you are doing.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States